HIV Infections, Tuberculosis
Conditions
Keywords
Levonorgestrel, Pharmacokinetics, Efavirenz, Dolutegravir, Rifampin
Brief summary
The purpose of this pharmacokinetic (PK) study was to evaluate if a double dose (3 mg) of levonorgestrel (LNG) overcomes known drug-drug interactions (DDIs) with efavirenz (EFV)-based antiretroviral therapy (ART) or rifampicin (RIF)-containing tuberculosis (TB) therapy. The safety of double-dose (3.0 mg) LNG versus standard-dose (1.5 mg) was also compared.
Detailed description
This pharmacokinetic (PK) study evaluated if a double dose (3.0 mg) of levonorgestrel (LNG) overcomes known drug-drug interactions (DDIs) with efavirenz (EFV)-based antiretroviral therapy (ART) or rifampicin (RIF)-containing tuberculosis (TB) therapy. The safety of double-dose (3.0 mg) LNG versus standard-dose (1.5 mg) was also compared. Participants were volunteers who did not require emergency contraception (EC) for contraception at the time of trial participation. This trial enrolled persons assigned female sex at birth who were 16 years of age or older. Group assignment was determined by disease status (HIV or TB; participants could not have been living with both HIV and TB), and, for those with HIV, by ART regimen at enrollment. Participants with HIV who were taking EFV-based ART were randomized to receive a standard dose LNG (Group A) or a double dose of LNG (Group B). Participants taking dolutegravir (DTG)-based ART were assigned to a standard dose of LNG (Group C). Participants in the continuation phase of active TB treatment taking RIF and isoniazid (INH) with or without ethambutol were assigned to a double dose of LNG (Group D). At study entry, participants in Groups A and C received a standard single dose of LNG. Participants in Groups B and D received a double dose of LNG. Intensive PK monitoring was conducted pre-dose, and after the LNG dose. Participants were expected to remain at the clinical site while the initial 8 hour PK samples were collected, and to return to the clinical site for the 24 and 48 hour samples. All participants completed self-report questionnaires to assess adherence to TB therapy and ART, menstrual history and patterns after LNG administration, and to collect adverse effects commonly reported with LNG (i.e., irregular bleeding patterns). Adherence to ART and RIF was also assessed by collecting hair samples and single plasma concentrations at entry. Participants were followed for 4 weeks.
Interventions
DRUGLevonorgestrel (LNG)
LNG tablet(s) were administered by mouth in a directly observed manner.
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
16 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Postmenarcheal female. * Note: Participant report and clinician's opinion were acceptable. * The following laboratory values obtained within 30 days prior to study entry by any US laboratory that had a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent, or at any ACTG network-approved non-US laboratory that operated in accordance with Good Clinical Laboratory Practices (GCLP) and participated in appropriate external quality assurance (EQA) programs. * Absolute neutrophil count (ANC) greater than or equal to 500 cells/mm\^3 * Platelet count greater than or equal to 50,000 platelets/mm\^3 * Hemoglobin greater than or equal to 8.0 g/dL * Aspartate transaminase (AST) less than 5 x upper limit of normal (ULN) * Alanine aminotransferase (ALT) less than 5 x ULN * Creatinine less than or equal to 1.5 x ULN * Total bilirubin less than or equal to 2.0 x ULN * Negative serum or urine pregnancy test within 30 days prior to study entry and within 48 hours prior to entry (if screening occurred more than 48 hours prior to entry) by any US clinic or US laboratory that had a CLIA certification or its equivalent, or used a point of care (POC)/CLIA-waived test, or at any network-approved non-US laboratory or non-US clinic that operated in accordance with GCLP and participated in appropriate EQA programs. The serum or urine pregnancy test must have had a sensitivity of at least 25 mIU/mL. * Had not had sex that could lead to pregnancy without contraception within 14 days prior to study entry as defined in the criteria below, according to participant self-report. * Contraception requirements * All participants agreed not to participate in a conception process (e.g., active attempt to become pregnant or in vitro fertilization) for the duration of the study. Women of reproductive potential, who were participating in sexual activity that could lead to pregnancy, agreed to use at least one reliable method of contraception while in the study. Acceptable forms of contraceptives included: * Male condom with or without a spermicidal agent * Diaphragm or cervical cap with spermicide * Non-hormonal intrauterine device (IUD) * Bilateral tubal ligation * Male partner vasectomy * Ability and willingness of participant or legal guardian/representative to have provided informed consent. * Body mass index (BMI) (kg/m\^2) available at entry. See the study protocol for BMI calculation instructions. * Note: A maximum of 5 participants with BMI greater than or equal to 30 kg/m\^2 were allowed in each arm B-D and a maximum of 3 participants in Arm A. * For participants with HIV: HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen, plasma HIV-1 RNA viral load. * Note: The term licensed referred to a US Food and Drug Administration (FDA)-approved kit, which was required for all investigational new drug (IND) studies, or for sites located in countries other than the United States, a kit that had been certified or licensed by an oversight body within that country and validated internally. Non-US sites were encouraged to use US FDA-approved methods for IND studies. * World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) guidelines mandated that confirmation of the initial test result must have used a test that was different from the one used for the initial assessment. A reactive initial rapid test was confirmed by either another type of rapid assay or an E/CIA that was based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), or a Western blot or a plasma HIV-1 RNA viral load. * For participants with HIV: Received a stable qualifying concomitant ART regimen containing either once-daily DTG 50 mg or EFV 600 mg with no changes in the components of their ART for at least 30 days prior to study entry. * For participants who were being treated for TB: HIV-negative at screening, documented within the prior 6 months by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen, or plasma HIV-1 RNA viral load. * Note: The term licensed referred to a US FDA-approved kit, which was required for all IND studies, or for sites located in countries other than the United States, a kit that had been certified or licensed by an oversight body within that country and validated internally. Non-US sites were encouraged to use US FDA-approved methods for IND studies. * WHO and CDC guidelines mandated that confirmation of the initial test result must have used a test that was different from the one used for the initial assessment. A reactive initial rapid test was confirmed by either another type of rapid assay or an E/CIA that was based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), or a Western blot or a plasma HIV-1 RNA viral load. * For participants who were living without HIV and being treated for TB: Received RIF and INH on a once daily dosing (7 days per week) schedule at study entry, after completion of the intensive phase of TB treatment. * Note: Inclusion of ethambutol as part of continuation phase of TB therapy was allowed. * Ability and willingness of participant to have been contacted remotely for study visits.
Exclusion criteria
* Known allergy/sensitivity or any hypersensitivity to LNG or components of the formulation. * Bilateral oophorectomy, hysterectomy, or postmenopausal * Note: Postmenopausal was defined as amenorrhea for at least 12 consecutive months prior to study entry (in the absence of medications known to induce amenorrhea), and had a documented follicle stimulated hormone-release factor (FSH) measurement greater than 40 mIU/mL or a result in the testing laboratory's menopausal range. If an FSH level was not available, 24 consecutive months of amenorrhea prior to study entry (in the absence of medications known to induce amenorrhea). * Note: Clinical assessment and clinician's opinion were acceptable. * Was currently pregnant, was within 6 weeks of delivery, or was currently breastfeeding an infant under 6 months of age. * Note: For recent pregnancy resolution during the first or second trimester, the participant was only eligible when the pregnancy test result was negative. * Receipt of LNG within 30 days prior to study entry. * Receipt of depo-medroxyprogesterone for 90 days prior to study entry, or norethisterone enanthate (NET-EN) within 60 days prior to study entry, or other hormonal contraceptives within 30 days prior to study entry. * Used any drugs other than RIF and EFV known to: 1) induce CYP3A4 system within 30 days prior to study entry, and 2) inhibit the CYP3A4 system within 7 days prior to study entry. See the study protocol for prohibited and precautionary medications. * Active drug or alcohol use or dependence that, in the opinion of the site investigator, would have interfered with adherence to study requirements. * Acute or serious illness that required systemic treatment and/or hospitalization within 14 days prior to study entry. * Other medical, psychiatric, or psychological condition that, in the opinion of the site investigator, would have interfered with completion of study procedures and or adherence to study drug. * For participants with HIV: Was currently receiving medications for TB infection. * For participants with HIV: Had missed one or more of the prescribed doses of HIV medications within 3 days prior to study entry. * Note: The entry visit could have been rescheduled within the screening period once the participant had taken all prescribed doses within 3 days prior to study entry. * For participants who were not living with HIV and were being treated for TB: Had missed one or more of the prescribed doses of TB medication within 3 days prior to study entry. * Note: The entry visit could have been rescheduled within the screening period once the participant had taken all prescribed doses within 3 days prior to study entry.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| LNG Area Under the Concentration-time Curve (AUC0-8h) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants | Intensive LNG PK samples at pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours post-dose | AUC for each participant was calculated from all available LNG concentrations measured over 8 hours using the linear up/log down version of trapezoidal rule (i.e., noncompartmental technique) using the software package Phoenix WinNonLin (Certara®). This version of the trapezoidal rule used linear interpolation between untransformed data up to Cmax, and between log-transformed data from Cmax through Clast. Assay lower limit of quantification (LLOQ) for LNG was 0.025 ng/mL; values \< LLOQ were imputed as 0 (if pre-dose) or as 0.0125 (if post-dose). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Concentration (Cmax) of LNG | Intensive LNG PK samples at pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours post-dose | Cmax for each participant was calculated as the maximum observed LNG concentration from LNG PK samples at pre-dose through 48 hours post-dose. Standard noncompartmental techniques were used to determine Cmax using the software package Phoenix WinNonLin (Certara®). |
| Minimum Concentration (Cmin) of LNG | Intensive LNG PK samples at pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours post-dose | Cmin for each participant was calculated as the minimum observed LNG concentration from LNG PK samples at pre-dose through 48 hours post-dose. Standard noncompartmental techniques were used to determine Cmin using the software package Phoenix WinNonLin (Certara®). Assay lower limit of quantification for LNG was 0.025 ng/mL; values \< LLOQ were imputed as 0 (if pre-dose) or as 0.0125 (if post-dose). |
| Oral Clearance (CL/F) of LNG | Intensive LNG PK samples at pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours post-dose | Apparent oral clearance (CL/F) for each participant was calculated as CL/F = dose/AUC0-24 or CL/F = dose/AUC0-48 of the observed LNG concentration from LNG PK samples at pre-dose through 48 hours post-dose. Standard noncompartmental techniques were used to determine CL/F using the software package Phoenix WinNonLin (Certara®). |
| Volume of Distribution (Vd) of LNG | Intensive LNG PK samples at pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours post-dose | Vd for each participant was calculated from observed LNG concentration from LNG PK samples at pre-dose through 48 hours post-dose. Standard noncompartmental techniques were used to determine Vd using the software package Phoenix WinNonLin (Certara®). |
| Number and Percentage of Participants Experiencing Either a Serious Adverse Event (SAE) or Adverse Event (AE) Potentially or Definitely Associated With Single Dose LNG Administration. | From Day 0 through study Day 28 | Adverse events were Graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017 and DAIDS AE Grading Table Addendum 1, Female Genital Grading Table for Use in Microbicide Studies, Version 1.0 - November 2007. Relationship of AE to study treatment was determined by the site, study core team, and DAIDS clinical representative. AEs evaluated in this outcome fulfilled the below criteria: * Potentially or definitely related to LNG dose * Grade 3 or higher AEs * Grade 2 of higher nausea, diarrhea, menorrhagia or metrorrhagia, and ectopic pregnancies |
| Time of Minimum Concentration (Tmin) of LNG | Intensive LNG PK samples at pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours pose-dose | Tmin for each participant was time to the minimum observed LNG concentration after the observed dose. |
| LNG Area Under the Concentration Time Curve (AUC0-24h) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants | Intensive LNG PK samples at pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours post-dose | AUC for each participant was calculated from all available LNG concentrations measured over 24 hours using the linear up/log down version of trapezoidal rule (i.e., noncompartmental technique) using the software package Phoenix WinNonLin (Certara®). This version of the trapezoidal rule used linear interpolation between untransformed data up to Cmax, and between log-transformed data from Cmax through Clast. Assay lower limit of quantification for LNG was 0.025 ng/mL; values \< LLOQ were imputed as 0 (if pre-dose) or as 0.0125 (if post-dose). |
| LNG Area Under the Concentration Time Curve (AUC0-48h) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants | Intensive LNG PK samples at pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours pose-dose | AUC for each participant was calculated from all available LNG concentrations measured over 48 hours using the linear up/log down version of the trapezoidal rule (i.e., noncompartmental technique) using the software package Phoenix WinNonLin (Certara®). This version of the trapezoidal rule used linear interpolation between untransformed data up to Cmax, and between log-transformed data from Cmax through Clast. Assay lower limit of quantification for LNG was 0.025 ng/mL; values \< LLOQ were imputed as 0 (if pre-dose) or as 0.0125 (if post-dose). |
| LNG Total Area Under the Concentration Time Curve AUCinf (Infinity) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants | Intensive LNG PK samples at pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours pose-dose | AUC for each participant was calculated from all available LNG concentrations measured to infinity hours using the linear up/log down version of trapezoidal rule (i.e., noncompartmental technique) using the software package Phoenix WinNonLin (Certara®). This version of the trapezoidal rule used linear interpolation between untransformed data up to Cmax, and between log-transformed data from Cmax through Clast. Assay lower limit of quantification for LNG was 0.025 ng/mL; values \< LLOQ were imputed as 0 (if pre-dose) or as 0.0125 (if post-dose). |
| Half-life (T1/2) of LNG | Intensive LNG PK samples at pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours post-dose | T1/2 for each participant was calculated using regression analysis when possible from the observed LNG concentration from LNG PK samples at pre-dose through 48 hours post-dose. Standard noncompartmental techniques were used to determine T1/2 using the software package Phoenix WinNonLin (Certara®). |
Countries
Botswana, Brazil, Kenya, Malawi, South Africa, Thailand, United States
Participant flow
Recruitment details
Participants enrolled from 18 sites. Sites were located in the United States and internationally (Botswana, Brazil, Kenya, Malawi, South Africa, Thailand). The first participant accrued in May 2019, and the last participant accrued in November 2020.
Pre-assignment details
Participants receiving EFV-based ART therapy were randomized between Group A (1.5mg dose of LNG) and Group B (3.0mg dose of LNG) in a 1:2 ratio using permuted blocks and institutional balancing. Participants living with HIV receiving DTG-based ART therapy and participants with TB receiving RIF-INH therapy were assigned to study groups C and D, respectively. Women with BMI greater than or equal to 30 kg/m2 were limited to no more than 5 within Groups B-D and no more than three within Group A.
Participants by arm
| Arm | Count |
|---|---|
| A: LNG 1.5 mg Among Participants on EFV-based ART (Randomized) Participants received 1.5 mg of LNG once orally on Day 0 and were followed post-treatment for 4 weeks. | 17 |
| B: LNG 3.0 mg Among Participants on EFV-based ART (Randomized) Participants received 3 mg of LNG once orally on Day 0 and were followed post-treatment for 4 weeks. | 35 |
| C: LNG 1.5 mg Among Participants on DTG-based ART (Assigned) Participants received 1.5 mg of LNG once orally on Day 0 and were followed post-treatment for 4 weeks. | 32 |
| D: LNG 3.0 mg Among Participants on RIF-INH TB Therapy (Assigned) Participants received 3 mg of LNG once orally on Day 0 and were followed post-treatment for 4 weeks. | 34 |
| Total | 118 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Lost to Follow-up | 0 | 0 | 1 | 0 |
| Overall Study | Protocol Violation | 0 | 1 | 1 | 0 |
Baseline characteristics
| Characteristic | B: LNG 3.0 mg Among Participants on EFV-based ART (Randomized) | Total | D: LNG 3.0 mg Among Participants on RIF-INH TB Therapy (Assigned) | A: LNG 1.5 mg Among Participants on EFV-based ART (Randomized) | C: LNG 1.5 mg Among Participants on DTG-based ART (Assigned) |
|---|---|---|---|---|---|
| Age, Continuous | 36 years | 34 years | 25 years | 42 years | 34 years |
| Gender Identity Cisgender | 35 Participants | 118 Participants | 34 Participants | 17 Participants | 32 Participants |
| Gender Identity Transgender spectrum | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| HIV-1 Infection Status HIV-1 infection absent | 0 Participants | 34 Participants | 34 Participants | 0 Participants | 0 Participants |
| HIV-1 Infection Status HIV-1 infection present | 35 Participants | 84 Participants | 0 Participants | 17 Participants | 32 Participants |
| Race/Ethnicity, Customized Asian | 20 Participants | 33 Participants | 2 Participants | 9 Participants | 2 Participants |
| Race/Ethnicity, Customized Black (Non-Hispanic) | 12 Participants | 73 Participants | 30 Participants | 7 Participants | 24 Participants |
| Race/Ethnicity, Customized Hispanic or Latino (Regardless of race) | 3 Participants | 10 Participants | 2 Participants | 1 Participants | 4 Participants |
| Race/Ethnicity, Customized Multiple Races | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized White (Non-Hispanic) | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Region of Enrollment Botswana | 0 Participants | 2 Participants | 2 Participants | 0 Participants | 0 Participants |
| Region of Enrollment Brazil | 3 Participants | 10 Participants | 2 Participants | 1 Participants | 4 Participants |
| Region of Enrollment Kenya | 0 Participants | 4 Participants | 4 Participants | 0 Participants | 0 Participants |
| Region of Enrollment Malawi | 0 Participants | 16 Participants | 6 Participants | 0 Participants | 10 Participants |
| Region of Enrollment South Africa | 12 Participants | 39 Participants | 18 Participants | 7 Participants | 2 Participants |
| Region of Enrollment Thailand | 20 Participants | 33 Participants | 2 Participants | 9 Participants | 2 Participants |
| Region of Enrollment United States | 0 Participants | 14 Participants | 0 Participants | 0 Participants | 14 Participants |
| Sex: Female, Male Female | 35 Participants | 118 Participants | 34 Participants | 17 Participants | 32 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 17 | 0 / 36 | 0 / 35 | 0 / 34 |
| other Total, other adverse events | 1 / 17 | 0 / 36 | 1 / 35 | 3 / 34 |
| serious Total, serious adverse events | 0 / 17 | 0 / 36 | 0 / 35 | 1 / 34 |
Outcome results
Primary
LNG Area Under the Concentration-time Curve (AUC0-8h) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants
AUC for each participant was calculated from all available LNG concentrations measured over 8 hours using the linear up/log down version of trapezoidal rule (i.e., noncompartmental technique) using the software package Phoenix WinNonLin (Certara®). This version of the trapezoidal rule used linear interpolation between untransformed data up to Cmax, and between log-transformed data from Cmax through Clast. Assay lower limit of quantification (LLOQ) for LNG was 0.025 ng/mL; values \< LLOQ were imputed as 0 (if pre-dose) or as 0.0125 (if post-dose).
Time frame: Intensive LNG PK samples at pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours post-dose
Population: Participants who took assigned dose of LNG and prescribed doses of background drugs (ART or TB treatment) and who had LNG PK concentrations available over the sampling time frame.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| A: LNG 1.5 mg Among Participants on EFV-based ART (Randomized) | LNG Area Under the Concentration-time Curve (AUC0-8h) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants | 52.13 hours * ng/mL |
| B: LNG 3.0 mg Among Participants on EFV-based ART (Randomized) | LNG Area Under the Concentration-time Curve (AUC0-8h) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants | 102.13 hours * ng/mL |
| C: LNG 1.5 mg Among Participants on DTG-based ART (Assigned) | LNG Area Under the Concentration-time Curve (AUC0-8h) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants | 80.50 hours * ng/mL |
| D: LNG 3.0 mg Among Participants on RIF-INH TB Therapy (Assigned) | LNG Area Under the Concentration-time Curve (AUC0-8h) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants | 124.39 hours * ng/mL |
90% CI: [0.81, 1.2]
90% CI: [1.12, 1.6]
90% CI: [1.27, 2.18]
90% CI: [0.45, 0.78]
Secondary
Half-life (T1/2) of LNG
T1/2 for each participant was calculated using regression analysis when possible from the observed LNG concentration from LNG PK samples at pre-dose through 48 hours post-dose. Standard noncompartmental techniques were used to determine T1/2 using the software package Phoenix WinNonLin (Certara®).
Time frame: Intensive LNG PK samples at pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours post-dose
Population: Participants who took assigned dose of LNG and prescribed doses of background drugs (ART or TB treatment) and who had LNG PK concentrations available over the sampling time frame.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| A: LNG 1.5 mg Among Participants on EFV-based ART (Randomized) | Half-life (T1/2) of LNG | 12.05 hours |
| B: LNG 3.0 mg Among Participants on EFV-based ART (Randomized) | Half-life (T1/2) of LNG | 11.79 hours |
| C: LNG 1.5 mg Among Participants on DTG-based ART (Assigned) | Half-life (T1/2) of LNG | 24.03 hours |
| D: LNG 3.0 mg Among Participants on RIF-INH TB Therapy (Assigned) | Half-life (T1/2) of LNG | 8.97 hours |
90% CI: [0.46, 0.59]
90% CI: [0.34, 0.43]
90% CI: [0.93, 1.25]
90% CI: [0.41, 0.56]
Secondary
LNG Area Under the Concentration Time Curve (AUC0-24h) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants
AUC for each participant was calculated from all available LNG concentrations measured over 24 hours using the linear up/log down version of trapezoidal rule (i.e., noncompartmental technique) using the software package Phoenix WinNonLin (Certara®). This version of the trapezoidal rule used linear interpolation between untransformed data up to Cmax, and between log-transformed data from Cmax through Clast. Assay lower limit of quantification for LNG was 0.025 ng/mL; values \< LLOQ were imputed as 0 (if pre-dose) or as 0.0125 (if post-dose).
Time frame: Intensive LNG PK samples at pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours post-dose
Population: Participants who took assigned dose of LNG and prescribed doses of background drugs (ART or TB treatment) and who had LNG PK concentrations available over the sampling time frame.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| A: LNG 1.5 mg Among Participants on EFV-based ART (Randomized) | LNG Area Under the Concentration Time Curve (AUC0-24h) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants | 81.64 hours * ng/mL |
| B: LNG 3.0 mg Among Participants on EFV-based ART (Randomized) | LNG Area Under the Concentration Time Curve (AUC0-24h) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants | 153.40 hours * ng/mL |
| C: LNG 1.5 mg Among Participants on DTG-based ART (Assigned) | LNG Area Under the Concentration Time Curve (AUC0-24h) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants | 157.56 hours * ng/mL |
| D: LNG 3.0 mg Among Participants on RIF-INH TB Therapy (Assigned) | LNG Area Under the Concentration Time Curve (AUC0-24h) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants | 213.69 hours * ng/mL |
90% CI: [0.6, 0.93]
90% CI: [0.9, 1.36]
90% CI: [1.29, 2.33]
90% CI: [0.32, 0.58]
Secondary
LNG Area Under the Concentration Time Curve (AUC0-48h) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants
AUC for each participant was calculated from all available LNG concentrations measured over 48 hours using the linear up/log down version of the trapezoidal rule (i.e., noncompartmental technique) using the software package Phoenix WinNonLin (Certara®). This version of the trapezoidal rule used linear interpolation between untransformed data up to Cmax, and between log-transformed data from Cmax through Clast. Assay lower limit of quantification for LNG was 0.025 ng/mL; values \< LLOQ were imputed as 0 (if pre-dose) or as 0.0125 (if post-dose).
Time frame: Intensive LNG PK samples at pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours pose-dose
Population: Participants who took assigned dose of LNG and prescribed doses of background drugs (ART or TB treatment) and who had LNG PK concentrations available over the sampling time frame.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| A: LNG 1.5 mg Among Participants on EFV-based ART (Randomized) | LNG Area Under the Concentration Time Curve (AUC0-48h) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants | 98.95 hours * ng/mL |
| B: LNG 3.0 mg Among Participants on EFV-based ART (Randomized) | LNG Area Under the Concentration Time Curve (AUC0-48h) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants | 180.25 hours * ng/mL |
| C: LNG 1.5 mg Among Participants on DTG-based ART (Assigned) | LNG Area Under the Concentration Time Curve (AUC0-48h) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants | 224.81 hours * ng/mL |
| D: LNG 3.0 mg Among Participants on RIF-INH TB Therapy (Assigned) | LNG Area Under the Concentration Time Curve (AUC0-48h) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants | 242.68 hours * ng/mL |
90% CI: [0.49, 0.78]
90% CI: [0.71, 1.1]
90% CI: [1.31, 2.4]
90% CI: [0.26, 0.47]
Secondary
LNG Total Area Under the Concentration Time Curve AUCinf (Infinity) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants
AUC for each participant was calculated from all available LNG concentrations measured to infinity hours using the linear up/log down version of trapezoidal rule (i.e., noncompartmental technique) using the software package Phoenix WinNonLin (Certara®). This version of the trapezoidal rule used linear interpolation between untransformed data up to Cmax, and between log-transformed data from Cmax through Clast. Assay lower limit of quantification for LNG was 0.025 ng/mL; values \< LLOQ were imputed as 0 (if pre-dose) or as 0.0125 (if post-dose).
Time frame: Intensive LNG PK samples at pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours pose-dose
Population: Participants who took assigned dose of LNG and prescribed doses of background drugs (ART or TB treatment) and who had LNG PK concentrations available over the sampling time frame.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| A: LNG 1.5 mg Among Participants on EFV-based ART (Randomized) | LNG Total Area Under the Concentration Time Curve AUCinf (Infinity) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants | 118.71 hours * ng/mL |
| B: LNG 3.0 mg Among Participants on EFV-based ART (Randomized) | LNG Total Area Under the Concentration Time Curve AUCinf (Infinity) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants | 196.83 hours * ng/mL |
| C: LNG 1.5 mg Among Participants on DTG-based ART (Assigned) | LNG Total Area Under the Concentration Time Curve AUCinf (Infinity) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants | 345.80 hours * ng/mL |
| D: LNG 3.0 mg Among Participants on RIF-INH TB Therapy (Assigned) | LNG Total Area Under the Concentration Time Curve AUCinf (Infinity) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants | 248.96 hours * ng/mL |
90% CI: [0.39, 0.63]
90% CI: [0.55, 0.86]
90% CI: [1.32, 2.45]
90% CI: [0.2, 0.38]
Secondary
Maximum Concentration (Cmax) of LNG
Cmax for each participant was calculated as the maximum observed LNG concentration from LNG PK samples at pre-dose through 48 hours post-dose. Standard noncompartmental techniques were used to determine Cmax using the software package Phoenix WinNonLin (Certara®).
Time frame: Intensive LNG PK samples at pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours post-dose
Population: Participants who took assigned dose of LNG and prescribed doses of background drugs (ART or TB treatment) and who had LNG PK concentrations available over the sampling time frame.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| A: LNG 1.5 mg Among Participants on EFV-based ART (Randomized) | Maximum Concentration (Cmax) of LNG | 15.10 ng/mL |
| B: LNG 3.0 mg Among Participants on EFV-based ART (Randomized) | Maximum Concentration (Cmax) of LNG | 24.90 ng/mL |
| C: LNG 1.5 mg Among Participants on DTG-based ART (Assigned) | Maximum Concentration (Cmax) of LNG | 18.65 ng/mL |
| D: LNG 3.0 mg Among Participants on RIF-INH TB Therapy (Assigned) | Maximum Concentration (Cmax) of LNG | 28.01 ng/mL |
90% CI: [0.96, 1.41]
90% CI: [1.21, 1.69]
90% CI: [1.17, 1.96]
90% CI: [0.6, 1]
Secondary
Minimum Concentration (Cmin) of LNG
Cmin for each participant was calculated as the minimum observed LNG concentration from LNG PK samples at pre-dose through 48 hours post-dose. Standard noncompartmental techniques were used to determine Cmin using the software package Phoenix WinNonLin (Certara®). Assay lower limit of quantification for LNG was 0.025 ng/mL; values \< LLOQ were imputed as 0 (if pre-dose) or as 0.0125 (if post-dose).
Time frame: Intensive LNG PK samples at pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours post-dose
Population: Participants who took assigned dose of LNG and prescribed doses of background drugs (ART or TB treatment) and who had LNG PK concentrations available over the sampling time frame.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| A: LNG 1.5 mg Among Participants on EFV-based ART (Randomized) | Minimum Concentration (Cmin) of LNG | 0.25 ng/mL |
| B: LNG 3.0 mg Among Participants on EFV-based ART (Randomized) | Minimum Concentration (Cmin) of LNG | 0.56 ng/mL |
| C: LNG 1.5 mg Among Participants on DTG-based ART (Assigned) | Minimum Concentration (Cmin) of LNG | 1.49 ng/mL |
| D: LNG 3.0 mg Among Participants on RIF-INH TB Therapy (Assigned) | Minimum Concentration (Cmin) of LNG | 0.41 ng/mL |
90% CI: [0.22, 0.61]
90% CI: [0.15, 0.44]
90% CI: [1.2, 3.7]
90% CI: [0.09, 0.32]
Secondary
Number and Percentage of Participants Experiencing Either a Serious Adverse Event (SAE) or Adverse Event (AE) Potentially or Definitely Associated With Single Dose LNG Administration.
Adverse events were Graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017 and DAIDS AE Grading Table Addendum 1, Female Genital Grading Table for Use in Microbicide Studies, Version 1.0 - November 2007. Relationship of AE to study treatment was determined by the site, study core team, and DAIDS clinical representative. AEs evaluated in this outcome fulfilled the below criteria: * Potentially or definitely related to LNG dose * Grade 3 or higher AEs * Grade 2 of higher nausea, diarrhea, menorrhagia or metrorrhagia, and ectopic pregnancies
Time frame: From Day 0 through study Day 28
Population: Participants who received LNG study treatment, grouped by LNG dose. LNG 1.5mg includes Group A (LNG 1.5 mg Among Participants on EFV-based ART (Randomized)) and Group C (LNG 1.5 mg Among Participants on DTG-based ART (Assigned)) participants. LNG 3.0mg includes Group B (LNG 3.0 mg Among Participants on EFV-based ART (Randomized)) and Group D (LNG 3.0 mg Among Participants on RIF-INH TB Therapy (Assigned)) participants.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| A: LNG 1.5 mg Among Participants on EFV-based ART (Randomized) | Number and Percentage of Participants Experiencing Either a Serious Adverse Event (SAE) or Adverse Event (AE) Potentially or Definitely Associated With Single Dose LNG Administration. | 2 Participants |
| B: LNG 3.0 mg Among Participants on EFV-based ART (Randomized) | Number and Percentage of Participants Experiencing Either a Serious Adverse Event (SAE) or Adverse Event (AE) Potentially or Definitely Associated With Single Dose LNG Administration. | 2 Participants |
p-value: 1Fisher Exact
Secondary
Oral Clearance (CL/F) of LNG
Apparent oral clearance (CL/F) for each participant was calculated as CL/F = dose/AUC0-24 or CL/F = dose/AUC0-48 of the observed LNG concentration from LNG PK samples at pre-dose through 48 hours post-dose. Standard noncompartmental techniques were used to determine CL/F using the software package Phoenix WinNonLin (Certara®).
Time frame: Intensive LNG PK samples at pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours post-dose
Population: Participants who took assigned dose of LNG and prescribed doses of background drugs (ART or TB treatment) and who had LNG PK concentrations available over the sampling time frame.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| A: LNG 1.5 mg Among Participants on EFV-based ART (Randomized) | Oral Clearance (CL/F) of LNG | 12.64 L/h |
| B: LNG 3.0 mg Among Participants on EFV-based ART (Randomized) | Oral Clearance (CL/F) of LNG | 15.24 L/h |
| C: LNG 1.5 mg Among Participants on DTG-based ART (Assigned) | Oral Clearance (CL/F) of LNG | 4.39 L/h |
| D: LNG 3.0 mg Among Participants on RIF-INH TB Therapy (Assigned) | Oral Clearance (CL/F) of LNG | 12.05 L/h |
90% CI: [3.17, 5.12]
90% CI: [2.33, 3.65]
90% CI: [0.82, 1.52]
90% CI: [2.65, 4.93]
Secondary
Time of Minimum Concentration (Tmin) of LNG
Tmin for each participant was time to the minimum observed LNG concentration after the observed dose.
Time frame: Intensive LNG PK samples at pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours pose-dose
Population: Participants who took assigned dose of LNG and prescribed doses of background drugs (ART or TB treatment) and who had LNG PK concentrations available over the sampling time frame.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| A: LNG 1.5 mg Among Participants on EFV-based ART (Randomized) | Time of Minimum Concentration (Tmin) of LNG | 47.07 hours |
| B: LNG 3.0 mg Among Participants on EFV-based ART (Randomized) | Time of Minimum Concentration (Tmin) of LNG | 47.95 hours |
| C: LNG 1.5 mg Among Participants on DTG-based ART (Assigned) | Time of Minimum Concentration (Tmin) of LNG | 47.61 hours |
| D: LNG 3.0 mg Among Participants on RIF-INH TB Therapy (Assigned) | Time of Minimum Concentration (Tmin) of LNG | 48.00 hours |
Secondary
Volume of Distribution (Vd) of LNG
Vd for each participant was calculated from observed LNG concentration from LNG PK samples at pre-dose through 48 hours post-dose. Standard noncompartmental techniques were used to determine Vd using the software package Phoenix WinNonLin (Certara®).
Time frame: Intensive LNG PK samples at pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours post-dose
Population: Participants who took assigned dose of LNG and prescribed doses of background drugs (ART or TB treatment) and who had LNG PK concentrations available over the sampling time frame.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| A: LNG 1.5 mg Among Participants on EFV-based ART (Randomized) | Volume of Distribution (Vd) of LNG | 276.70 L |
| B: LNG 3.0 mg Among Participants on EFV-based ART (Randomized) | Volume of Distribution (Vd) of LNG | 294.92 L |
| C: LNG 1.5 mg Among Participants on DTG-based ART (Assigned) | Volume of Distribution (Vd) of LNG | 169.05 L |
| D: LNG 3.0 mg Among Participants on RIF-INH TB Therapy (Assigned) | Volume of Distribution (Vd) of LNG | 156.31 L |
90% CI: [1.66, 2.65]
90% CI: [0.89, 1.39]
90% CI: [0.87, 1.66]
90% CI: [1.24, 2.45]